LuMend Overview

LuMendÔ Inc., a developer and manufacturer of innovative technology to treat chronic total occlusions (CTOs). LuMend (Redwood City, California) has launch its fifth-generation catheter platform, the Front-runner X39 CTO Catheter. The X39 is about 50% smaller than previous generations. The company also reported safety data for blunt micro-dissection, the technology behind the Frontrunner...More»

LuMendÔ Inc., a developer and manufacturer of innovative technology to treat chronic total occlusions (CTOs). LuMend (Redwood City, California) has launch its fifth-generation catheter platform, the Front-runner X39 CTO Catheter. The X39 is about 50% smaller than previous generations. The company also reported safety data for blunt micro-dissection, the technology behind the Frontrunner catheters. The X39 Catheter is used to treat complete blockages in the coronary arteries. It has a distal tip size of .039, with a 30% increase in distal tip opening power compared to previous generations. The company said that because of the catheter's small size, it handles like a guide wire. It uses controlled, blunt micro-dissection to gently separate atherosclerotic plaque, creating a passage through the CTO. Acquired by Johnson & Johnson Gateway.«Less